At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 96 enrolled
Drug / intervention
Gabapentin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Gabapentin for Relapse Prevention: Alcohol Withdrawal Effects
In Brief
A Phase 2 clinical trial evaluating Gabapentin and Placebo for Alcohol Use Disorder and Alcohol Withdrawal. Completed, enrolled 96 participants across 1 site.
Detailed Summary
This treatment study is a 16-weeks outpatient clinical trial where subjects with alcohol dependence will get medication, which might help them to reduce or stop their drinking, or a placebo ( placebo is a capsule that looks the same as the investigational drug, but has no real medication. It is a "sugar pill").
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Use Disorder, Alcohol Withdrawal
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartNov 2014
First PostedJan 2015
Primary CompletionAug 2018
TodayJul 2026
First PostedJan 29, 2015
Enrollment StartNov 1, 2014
Primary CompletionAug 27, 2018
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 11.4 years ago
Interventions
Gabapentindrug
gaba potentiating medication
Placebodrug
a pill that looks exactly like the active medication but does not contain medication